| Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. | |
| | |
MedLine Citation:
|
PMID: 9794093 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study deals with the potential therapeutic effect of orotic acid (OA) and Mg Orotate (MgO) on myocardial degeneration and the development of congestive heart failure in cardiomyopathic (CM) hamsters of the UM-X7.1 line. Two major age groups (group I, < 30 days and group II, > 180 days old) were used in these experiments, which lasted 30 and 50 days, respectively; the orotic salts were incorporated (10%) into Purina Lab Chow given ad libitum. Macroscopic and microscopic assessment of pathologic changes together with ECG recordings revealed that MgO treatment significantly reduces myocardial damage, especially the severity of calcific changes. ECG recordings clearly demonstrated a significant shortening of QTc and PR intervals, resulting in partial electrical stabilization of failing hearts, with a significant delay in systemic congestive changes. The prevention of heart lesions was less evident in animals receiving OA, but both preparations proved to be equally efficient in prolonging survival of the CM hamsters. |
| | |
Authors:
|
G Jasmin; L Proschek |
Related Documents
:
|
12962163 - Thiazolidinedione-associated congestive heart failure and pulmonary edema. 10819393 - Aorto caval fistula--the "bursting heart syndrome". 18490313 - Longitudinal plane colour tissue-doppler myocardial velocities and their association wi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 12 Suppl 2 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 1998 Sep |
Date Detail:
|
Created Date: 1999-01-14 Completed Date: 1999-01-14 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 189-95 Citation Subset: IM |
Affiliation:
|
Département de pathologie, Université de Montréal, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Body Weight / drug effects Calcinosis / etiology, pathology, prevention & control Cardiomyopathies / complications, genetics, pathology, prevention & control* Cricetinae Diet Electrocardiography Female Heart Failure / etiology, pathology, physiopathology, prevention & control* Male Myocardium / pathology Organ Size / drug effects Orotic Acid / administration & dosage, analogs & derivatives*, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
34717-03-8/magnesium orotate; 65-86-1/Orotic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleoti...
Next Document: On the significance of magnesium in extreme physical stress.